Shetzline Michael 4

What Happened
Michael Shetzline, Senior Vice President, Chief Medical Officer and Head of Research & Drug Development at Ironwood Pharmaceuticals (IRWD), received a grant of 136,612 restricted stock units (RSUs) on March 10, 2026. The award was recorded at $0.00 per share (a non-cash compensation award), so there was no purchase price or immediate cash value reported on the Form 4.

Key Details

• Transaction type: Award/Grant (Form 4 transaction code A)
• Transaction date: 2026-03-10; Filing date (accession): 2026-03-12 (filed timely)
• Shares granted: 136,612 RSUs; price reported: $0.00; reported acquisition value: $0
• Vesting: Award vests 25% on each approximately annual anniversary of the grant (per footnote — annual performance award)
• Shares owned after transaction: not disclosed in the provided filing details
• No 10b5-1 plan, tax-withholding, or immediate sale noted in the filing

Context
RSUs are compensation awards that convert to shares only as they vest; this grant spreads potential ownership over roughly four years (25% per year). Because this was a non-cash, performance-based award, it is a routine executive compensation action and not an open-market purchase or sale.